Search

everythinglearnresearchcommunity

for

Search:↓

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Exercise may help reduce treatment side effects and improve survival in metastatic colorectal cancer.

5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Chemotherapy-induced hair loss significantly affects patients' well-being, and nurses are key in helping them cope, but more research is needed to find effective treatments.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Some breast cancer chemotherapy can cause permanent hair loss.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Hair and nail changes can indicate health issues, including cancer and side effects from cancer treatments.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.

Hes1 protein is important for hair growth and regeneration, and could be a potential treatment for hair loss.

Retinoids can prevent skin cancer in high-risk people but have side effects and require more research on dosing and effectiveness.

No definitive link between finasteride and male breast cancer, but further research is needed.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

The treatment combination is effective and generally safe for lung cancer.

Targeting METTL1 may help slow papillary thyroid cancer growth and spread.

Onions may help reduce cancer risk and obesity-related issues.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Six key genes can predict bladder cancer outcomes and may serve as prognostic biomarkers.

Physical activity, height, and smoking affect prostate cancer risk.

Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.

KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.

A group has developed therapies that show promise for treating cancer and various other conditions.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

CRISPR/Cas systems show promise for cancer treatment by targeting miRNAs, but delivery and specificity challenges remain.

Age, race, family history, and certain genetic factors increase prostate cancer risk.